Business Wire

The Estée Lauder Companies Announces Chris Good, Group President, North America to Retire After Exceptional Career

16.11.2021 15:00:00 EET | Business Wire | Press release

Share

Today, The Estée Lauder Companies (NYSE:EL) (“ELC”) announced that Chris Good, Group President, North America, after nearly 25 years with the company, has made the decision to retire effective June 30, 2022. The successor to Chris’ role will be announced shortly, and Chris will partner closely with this individual to support a smooth and successful transition.

“Chris is a visionary, global leader who is deeply admired at ELC and recognized across the beauty industry worldwide. With his extensive international background, Chris’ leadership agility and deep insights into our diverse markets and consumers around the world have made an indelible impact on our business,” said Fabrizio Freda, President and Chief Executive Officer. “Known for his extraordinary business acumen, ability to build high-performing teams, and his track record of achieving strong results in both nascent and established markets globally, Chris has exemplified a commitment to excellence.”

For the past five years, Chris led ELC’s North America business, a highly complex, competitive, and fast-evolving prestige beauty landscape. He oversaw the region’s pivotal retail and organizational transformation, establishing critical capabilities to drive growth and operational efficiencies.

Additionally, Chris elevated data analytics and insights to unlock new and granular opportunities across brands, consumers, and channels. His expertise in channel strategy has accelerated the online business and strengthened the region’s retail relationships, optimizing brick-and-mortar by prioritizing high-performing doors and specialty-multi, and driving brand-building distribution in freestanding stores and emerging channels through modernized omni-experiences.

Chris consistently transformed the business while running it – pivoting with agility and resilience to accelerate recovery in a dynamic environment, while navigating numerous headwinds in North America. Over the past year and a half, he collaborated with his leadership team to steer the region through the complexities of the COVID-19 pandemic, as well as broader macro and social issues, leading with the company’s values and the wellbeing of ELC’s people in mind.

Under Chris’ steady leadership, the North American business returned to growth in fiscal year 2021 and has continued its momentum into the first quarter of fiscal year 2022. To start the new fiscal year, North America delivered strong net sales growth with sales increases across every category. Chris and his leadership team have laid a healthy foundation for long-term, sustainable recovery and growth in North America.

Chris started at ELC in Clinique Marketing in the U.K. and Ireland in 1987. After a period away from the company, where Chris took on senior marketing executive and general management roles for Unilever across Europe, North America and Asia/Pacific, he returned in 2000, as General Manager/Regional Vice President for Clinique, Asia/Pacific, where he helped grow the China and Japan affiliates in their early days. In 2005, he was named General Manager of the recently-established Russian affiliate and in 2008, he became Senior Vice President, Central and Eastern Europe, Middle East, India, and Africa.

Chris was appointed Managing Director, U.K. and Ireland in 2012. While there, he helped pioneer the company’s successful evolution from a traditional department store model into a diversified omnichannel business, leading in brand-building channels such as e/m-commerce and specialty-multi. He was promoted to President, U.K. and Ireland in 2014, and during his tenure, the business generated consistent double-digit, compound annual sales growth and tripled online net sales.

“We are grateful for Chris’ tremendous contributions to our business, and the resolve and dedication he has demonstrated to push boundaries, invent the unexpected and bring the best to ELC and beyond. He has championed our company values and embodied our culture both in the Field and alongside his teams, continuously fueling collaboration and creativity,” said William P. Lauder, Executive Chairman. “Across our global ELC family and the wider industry, Chris has nurtured strong relationships and his hospitable nature, dynamic leadership, and deep retail expertise will be truly missed. On behalf of the company and the Lauder family, I would like to wish Chris the very best in his well-deserved retirement.”

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers and sellers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin Paris, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.

ELC-C
ELC-L

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors: Rainey Mancini
rmancini@estee.com

Media: Jill Marvin
jimarvin@estee.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release

Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila

PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye